Fig 1: CXCR2-MSCEGFP therapy reduces inflammatory response in IBD(A) Representative H&E images of colon sections of control, IBD, MSCEGFP-treated, and CXCR2-MSCEGFP-treated mice at 24 h post-injection. Histopathological score of colon tissue from control, PBS-treated, MSCEGFP-treated, and CXCR2-MSCEGFP-treated mice is presented (right). Data are presented as means ± SDs for each group (n = 3 mice/group from 3 independent experiments). Scale bar, 100 μm. (B) MPO activity of colon tissue homogenates obtained from each group during TNBS-induced IBD (24 h post-injection) was examined by ELISA. Data are presented as means ± SDs for individual mice. (C) ELISA was used to measure the concentrations of IL-10, IFN-γ, IL-12, IL-13, TNF-α, and IL-17 in homogenates of colons obtained from each group 24 h post-injection. Data are presented as means ± SDs for each group (n = 3 mice/group from 3 independent experiments). (D) MSCEGFP and CXCR2-MSCEGFP were i.v. injected into IBD mice. Representative confocal images of colon sections after 3 days, are displayed. Signals: human nuclei, green; IL-10, red; DAPI, blue. Scale bar, 100 μm. (E) The percentages of IFN-γ/CD4+ cells and IL-10/CD4+ cells in colon tissues were measured by flow cytometry. The data are representative of 3 independent experiments. Quantifications are presented as means ± SDs. (F) The percentages of IFN-γ/macrophages and IL-10/macrophages in colon tissues were measured by flow cytometry. The data are representative of 3 independent experiments. Quantifications are presented as means ± SDs. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.